Abstract The purpose of this study was to model data from a head to head comparison of the in vivo fate of hyperbranched PAMAM dendrimers with linear HPMA copolymers in order to understand the influence of molecular weight (MW), hydrodynamic size (R h ), and polymer architecture on biodistribution in tumor-bearing mice using compartmental pharmacokinetic analysis. Blood concentration data were modeled by twocompartment analysis using Winnonlin® to obtain elimination clearance (E.CL) and blood exposure (AUC blood ). Renal clearance (CL R ) was calculated from urine data collected over 1 week. A blood-tumor link model was fitted to experimental blood and tumor data by varying the tumor extravasation (K 4 , K 6 ) and elimination (K 5 ) rate constants using multivariable constrained optimization solver in Matlab®. Tumor exposures (AUC tumor ) were computed from area under the tumor concentration time profile curve by the linear trapezoidal method. Along with MW and R h , polymer architecture was critical in affecting the blood and tumor pharmacokinetics of the PAMAM-OH dendrimers and HPMA copolymers. Elimination clearance decreased more rapidly with increase in hydrodynamic size for PAMAM-OH dendrimers as compared to HPMA copolymers. HPMA copolymers were eliminated renally to a higher extent than PAMAM-OH dendrimers. These results are suggestive of a difference in extravasation
of polymers of varying architecture through the glomerular basement membrane. While the linear HPMA copolymers can potentially reptate through a pore smaller in size than their hydrodynamic radii in a random coil conformation, PAMAM dendrimers have to deform in order to permeate across the pores. With increase in molecular weight or generation, the deforming capacity of PAMAM-OH dendrimers is known to decrease, making it harder for higher generation PAMAM-OH dendrimers to sieve through the glomerulus as compared to HPMA copolymers of comparable molecular weights. PAMAM-OH dendrimer had greater tumor extravsation rate constants and higher tumor to blood exposure ratios than HPMA copolymers of comparable molecular weights which indicated that in the size range studied, when in circulation, PAMAM-OH dendrimers had a higher affinity to accumulate in the tumor than the HPMA copolymers.
Keywords Poly(amido amine) (PAMAM) dendrimer . N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer . Polymer architecture . Compartmental pharmacokinetics Abbreviations PAMAM poly(amido amine) PAMAM-OH hydroxyl-terminated poly(amido amine) HPMA N-(2-hydroxypropyl)methacrylamide GX.0-OH hydroxyl-terminated PAMAM, generation X.0 R h hydrodynamic radius MW molecular weight C p concentration in the plasma C t1 concentration in tumor compartment 1 C t2 concentration in tumor compartment 2 AUC blood area under the curve of the blood concentration profile AUC tumor area under the curve of the tumor concentration profile E.CL elimination clearance CL R renal clearance AIC Akaike information criterion
Introduction
Biocompatible water-soluble polymers have been widely used as carriers for a variety of drug-delivery and in vivo imaging applications [1] . Polymeric carriers can have varying architectures such as linear, dendritic, comb-shaped, and star-shaped [2] . Poly(amido amine) or PAMAM dendrimers are a class of hyperbranched polymers which have shown promise as drug carriers for targeted delivery to solid tumors [3] [4] [5] . PAMAM dendrimers have an extraordinary level of structural control and multi-functionalizing potential. With every increase in generation of the PAMAM dendrimer, the molecular weight and number of surface groups double and their molecular conformation become more rigid. The pharmacokinetics of PAMAM dendrimers has been correlated to its physicochemical properties such as generation or molecular weight, chemical composition of core, and nature of surface groups as well as type of surface modification [6] [7] [8] . Poly(N-(2-hydroxypropyl)methacrylamide) (HPMA) copolymers are a class of linear polymers with side chains that can be terminated in drugs, targeting moieties and imaging agents [9, 10] . Such copolymers have been well characterized for the influence of co-monomer structure, composition and charge on solution properties, molecular conformation, as well as in vivo biodistribution and pharmacokinetics [11] [12] [13] .
Along with the molecular weight, polymer architecture and hydrodynamic size are also known to affect the biodistribution and consequently the pharmacokinetics of the polymeric carriers [14] [15] [16] [17] . The shape and ability of macromolecules to deform have been reported to influence their glomerular filtration and consequently elimination clearance and blood exposure [15] . Previously in our laboratory, we have conducted a head to head comparison of the in vivo fate of hyperbranched hydroxyl-terminated poly(amido amine) or PAMAM-OH dendrimers with linear HPMA copolymers (containing hydroxyl-terminated side chains) of comparable molecular weights in tumor-bearing mice. It was observed that along with molecular weight, hydrodynamic size, and polymer architecture were critical in affecting the accumulation of these polymers in the tumor and elimination organs such as kidney and liver [17] .
To gain further insight into the biological fate of these polymers of varying architecture, it is essential to quantify the in vivo kinetics of these drug carriers after having obtained the tissue distribution information. The purpose of this study was to model the previously obtained experimental data on the biodistribution of HPMA copolymers and PAMAM-OH dendrimers by compartmental pharmacokinetic analysis. We also experimentally investigated an additional probe-HPMA copolymer (131 kDa), which was chemically similar to the other HPMA copolymers under study and comparable in molecular weight to PAMAM G7.0-OH. By modeling the biodistribution data, we quantified the pharmacokinetic parameters of these polymeric carriers of varying hydrodynamic sizes and architecture in order to understand their effect on in vivo kinetics.
Materials and methods

Data collection
Polymer synthesis, characterization, and radiolabeling The synthesis and characterization of the polymers are described previously [17] . Briefly, HPMA copolymers containing ethanolamine side chains were synthesized to obtain weight average molecular weights of 26, 52, and 131 kDa in order to have comparable molecular weights with PAMAM dendrimers (purchased from Sigma Aldrich, MO), hydroxylterminated, generations 5.0 (G5.0-OH-29 kDa), 6.0 (G6.0-OH-58 kDa), and 7.0 (G7.0-OH-117 kDa), respectively. Polymers were characterized using a size exclusion chromatography (SEC) system with Superose 6 TM 10/300 GL column (GE Healthcare, Piscataway, NJ) to estimate molecular weight using HPMA homopolymer standards of known molecular weights. They were further characterized for hydrodynamic radius (R h ) using a Dynamic Light Scattering (DLS) detector (Helleos II) attached to the FPLC system and analyzed using Astra TM 5.3.4.13 software (Wyatt Technologies, Santa Barbara, CA). The zeta potential of polymers dispersed in distilled (DI) water at a concentration of 5.0 mg/ml was measured using a Malvern Instruments Zetasizer Nano ZS (Westborough, MA). The HPMA copolymers, containing tyrosine groups in the side chains, were reacted with Na 125 I (American Radiolabeled Chemicals, St. Louis, MO) while PAMAM dendrimers were reacted with 125 Iodine-labeled Bolton Hunter reagent (American Radiolabeled Chemicals, St. Louis, MO) to facilitate radioactive detection. The synthesis and characterization of all the polymers described above, with the exception of HPMA copolymer (131 kDa), were reported previously [17] . The HPMA copolymer (131 kDa) was synthesized (Detailed methodology in Section I, online resource) and characterized in order to provide a random-coil system comparable in MW to the hyperbranched PAMAM G7.0-OH.
In vivo biodistribution The in vivo biodistribution of the polymers in ovarian tumor-bearing mice was described previously [17] . Briefly, animals were inoculated with approximately 1×10 6 A2780 cells directly beneath the left ovarian bursa. Six groups of tumor-bearing mice were dosed intravenously by tail vein injection with 50 mg/kg of radiolabeled G5.0-OH, HPMA copolymer (26 kDa), 40 mg/kg of HPMA copolymer (52 kDa), and 20 mg/kg of PAMAM G6.0-OH, G7.0-OH, and HPMA copolymer (131 kDa) in 0.2 mL sterile saline. The mice were sacrificed at defined time points of 5 and 30 min, 2, 6, and 24 h, and 1 week. All major organ systems were collected including blood, heart, lung, liver, spleen, kidney, tumor, brain, and the rest of the carcass that included skin, muscle, and intestines. Urine and stool were collected by housing animals in metabolic cages and were pooled for all the animals for a given study group at a particular time point. Blood and homogenized carcass were sampled whereas the rest of the organs collected were measured as a whole for radioactive count using a Gamma counter (Cobra Autogamma, Perkin Elmer, Wellesley, MA). All animal experiments were performed in accordance with the University of Utah IACUC guidelines under approved protocols. More details on the methodology of data collection are reported in the previously published biodistribution study [17] . The radioactive readings obtained in counts per minute from blood, tumor, and urine were expressed as milligram of dose (weight of polymer) using the correlation of administered dose in mg/kg of mouse and total counts per minute of radioactivity measured for each dose. The blood weights of each mouse were expressed in milliliters (volume of blood) assuming the density of mouse blood to be 1.05 g/ ml [18] . Consequently, the blood concentration of polymers (C p ) was expressed as the weight of PAMAM-OH dendrimer/HPMA copolymer per unit volume of blood (mg/ml). The organ accumulation for tumor was expressed in milligram of polymer per gram of organ weight (mg/g). The biodistribution of all the polymers described above, with the exception of HPMA copolymer (131 kDa), was reported previously [17] . The biodistribution of HPMA copolymer (131 kDa) was evaluated ( Figure S1 -S3, Section II, online resource) in order to provide a third data point in the correlation of pharmacokinetic parameters of the HPMA copolymer series to hydrodynamic size as well as to provide a head to head comparison with pharmacokinetics of PAMAM G7.0-OH of comparable MW.
Pharmacokinetic analysis
The biodistribution data were modeled using a naïve averaged data approach. Blood concentration data were fitted to one and two-compartmental models with single bolus input using WinNonlin® 2.1 (Pharsight, a Certara Company, St. Louis, MO). The Akaike Information Criterion values obtained from each of the model fits indicated that the two-compartment model fit the blood concentration time profile better than the one-compartment model (Table S1 , Section III, online resource). The blood data were therefore modeled by two-compartment analysis using Winnonlin® 2.1 to obtain elimination clearance (E.CL) and blood exposure (AUC blood ). Renal clearance (CL R ) was calculated from urine data collected over 1 week (Equations (1) and (2), Section III, online resource).
A compartmental model was set up in order to link the blood and the tumor compartments (Fig. 1) . The model allowed a two-compartmental distribution for the blood between the central blood (C p ) and the peripheral fast distribution compartment (C f ; as determined from fitting plasma data alone). The tumor compartment was subdivided into two compartments, linked serially to the blood. The first compartment (C t1 ) allowed elimination of the polymers back into the blood. The second tumor compartment (C t2 ) did not allow elimination in order to account for the tumor retention of the higher MW polymers. The blood elimination (K 1 ) and distribution (K 2 , K 3 ) rate constants were fixed as per the two-compartmental distribution of the plasma data. The model was fitted to experimental blood and tumor data by varying the tumor extravasation (K 4 , K 6 ) and elimination (K 5 ) rate constants using multivariable constrained optimization solver in Matlab® (compartmental model equations and optimization code given in Section VII, Online Resource). The model assumed that the presence of the tumor did not alter the blood pharmacokinetics.
Tumor exposures (AUC tumor ) were computed from area under the tumor concentration time profile curve by the linear trapezoidal method. Blood and tumor exposures were dose normalized assuming linear pharmacokinetics over the dose ranges studied for the polymers (20-50 mg/ kg).
Results
Polymer characteristics
The detailed characteristics of the polymers employed in the study are summarized in Table 1 . The addition of the experimental points for high molecular weight HPMA copolymer (131 kDa), comparable in molecular weight to G7.0-OH (117 kDa), has provided more insight into the hydrodynamic size trends as a function of molecular weight for the HPMA copolymer series. The PAMAM-OH dendrimers under study were generations 5.0, 6.0, and 7.0 with hydroxyl surface groups chosen such that their molecular weights (29, 58 , and 117 kDa) lie in the physiologically relevant range for kidney filtration, extended plasma circulation, and tumor retention. The HPMA copolymers (26, 52 , and 131 kDa) have comparable molecular weights with PAMAM G5.0-OH, G6.0-OH, and G7.0-OH dendrimers, respectively. Polymer architecture affected molecular conformation and hence hydrodynamic size of the PAMAM dendrimers and HPMA copolymers of comparable molecular weights. The increment in hydrodynamic size (R h ) of HPMA copolymers with increase in molecular weight (MW) was greater than the increment in R h of PAMAM dendrimers with the same increments in MW (Fig. 2) . Below an MW of about 40 kDa, PAMAM G5.0-OH (MW0 29 kDa) was larger (R h 02.3 nm) than HPMA copolymer of comparable MW (MW026 kDa, R h 01.4 nm). Above this cutoff of 40 kDa, the opposite trend was observed. PAMAM G6.0-OH (MW058 kDa, R h 03.0 nm) was smaller than HPMA copolymer of comparable MW (MW 052 kDa, R h 03.3 nm). The trend was consistent amongst the higher MW polymers with the HPMA copolymer (MW0131 kDa, R h 08.2 nm) being twice the hydrodynamic size of G7.0-OH (MW 0117 kDa, R h 04.0 nm) of comparable MW. The PAMAM dendrimers had hydroxyl surface groups while the HPMA copolymers had hydroxyl-terminating side chains to provide a fairly neutral charge for both the polymers of varying architecture. However, HPMA copolymers of 26 and 131 kDa had a slightly negative charge due to a hydrolysis side reaction, resulting in pendent carboxylic acid groups. This side reaction can occur in the final aminolysis step in the copolymer synthesis reaction that imparts a majority of hydroxyl-terminated surface groups.
Pharmacokinetic analysis
The polymers showed a biphasic exponential blood circulation with an apparent fast distribution component and a much slower elimination component (Fig. 3a) . The twocompartmental pharmacokinetic parameter estimates showed a significant difference across molecular weights for each of the polymer series-PAMAM-OH dendrimers and HPMA copolymers ( Table 2 ). Details of the results are discussed below:
Blood exposure
The dose normalized blood exposure (AUC blood /dose) increased with increase in molecular weight or hydrodynamic size for the PAMAM-OH dendrimers ( Table 2 , Fig. 3b ). The HPMA copolymers had similar blood exposures for the 26 and 52 kDa copolymers, while the blood exposure increased drastically for the HPMA copolymer (131 kDa; Table 2 , Fig. 3b ). Consistent with the trend for elimination clearance (the "Elimination clearance-correlation with hydrodynamic size" section), HPMA copolymer (26 kDa) (R h 01.4 nm) had a higher blood exposure in spite of being smaller in hydrodynamic size than G5.0-OH (R h 02.3 nm) of comparable MW. The opposite was seen for HPMA copolymer (52 kDa; R h 03.3 nm) and G6.0-OH (R h 03.0 nm) of comparable MW with the hyperbranched dendrimer showing higher blood exposure than HPMA copolymer of comparable MW even though the dendrimer was slightly smaller than the HPMA copolymer. This observation can also be attributed to the trend in elimination clearance where the linear HPMA copolymer on the threshold of kidney filtration eliminated faster than the branched dendrimer (elaborated in the "Elimination clearance-correlation with hydrodynamic size" section). Owing to its hydrodynamic size being twice that of G7.0-OH (R h 04.0 nm), HPMA copolymer (131 kDa; R h 08.2 nm) had a much higher blood exposure than G7.0-OH of comparable MW.
Elimination clearance-correlation with hydrodynamic size
Elimination clearance decreased with increase in molecular weight within each of the polymer series ( Table 2 ). The hydrodynamic diameter of G5.0-OH (29 kDa) and HPMA (26 kDa) was below the threshold diameter for kidney filtration (6.0 nm) [19] . In spite of being greater in hydrodynamic size, the blood elimination clearance of G5.0-OH (R h 02.3 nm) was significantly higher than that of HPMA (26 kDa; R h 01.4 nm) of comparable molecular weight. In this size range, the highly compact structure of the PAMAM dendrimer may facilitate extravasation faster than the linear HPMA copolymer, explaining its faster rate of disappearance from the blood compartment. These observations demonstrate that polymer architecture affected elimination clearance below kidney filtration threshold. G6.0-OH (58 kDa) and HPMA copolymer (52 kDa) were on the threshold of kidney filtration cutoff diameter (6.0 nm). Their elimination clearances were comparable with the HPMA (R h 03.3 nm) being eliminated from the blood slightly faster than the G6.0-OH (R h 03.0 nm). This difference was not statistically significant. However this observation suggests that at the kidney filtration threshold size, the linear copolymer was eliminated faster than the hyperbranched dendrimer, even though it was slightly greater in hydrodynamic size. However, for the higher molecular weight polymers, G7.0-OH has a faster clearance than the HPMA copolymer (131 kDa) of comparable MW. In this range of MW, the G7.0-OH was almost half the hydrodynamic size of HPMA (131 kDa) and the vast difference in hydrodynamic size governed the elimination clearance.
Over the molecular weight range studied, elimination clearance decreased log linearly with increase in hydrodynamic size within each of the polymer series (Fig. 4) . However, elimination clearance decreased more rapidly for PAMAM-OH dendrimers with increase in hydrodynamic volume as compared to HPMA copolymers indicated by slopes (Fig. 4) . This can be attributed to the effect of architecture on the change in molecular conformation of polymers with increase in molecular weight (elaborated in detail in the "Discussion" section) [20, 21] .
The observed trend of decrease in elimination clearance is only expected to hold over this range of molecular weights since the polymers transition from being small enough to be readily filtered through the kidney (G5.0-OH and HPMA copolymer (26 kDa)), to being on the threshold of kidney filtration (G6.0-OH, HPMA copolymer (52 kDa)), and further to being long circulating in the blood (G7.0-OH, Fig. 1 HPMA copolymer (131 kDa)) with a minimal renal clearance. We do not expect this trend to hold outside of this molecular weight or size range, where the elimination clearance is likely to be independent of hydrodynamic size, although such studies warrant further investigation [22] .
Renal clearance
Renal clearance decreased with increase in hydrodynamic size for each of the polymer series ( Table 2 , Fig. 5 ). However, at comparable molecular weights, linear HPMA copolymers were eliminated renally to a higher extent (by an order of magnitude) than hyperbranched PAMAM-OH dendrimers ( Table 2 , Fig. 5 ). In spite of the hydrodynamic size of HPMA copolymer (131 kDa; R h 08.2 nm) being double that of G7.0-OH (R h 04.0 nm), HPMA copolymer (131 kDa) was eliminated renally to a greater extent than G7.0-OH. This can be attributed to the unique ability of a linear polymer to reptate through a renal filtration pore while the branched polymer has to deform in order to pass through [15, 23] . Renal clearance was significantly less than the total elimination clearance for all of the polymers under study. This is indicative of the presence of other clearance mechanisms, potentially through the liver and the spleen.
Tumor exposure
Tumor concentration peaked at about 0.5-6 h for the polymers under study with the larger molecular weight polymers showing a greater T max than the lower molecular weight polymers (Fig. 6a) indicating a longer diffusion time for the larger polymers into the tumor. The dose normalized tumor exposure (AUC tumor /dose) increased with increase in molecular weight or hydrodynamic size within a given polymer series ( Table 2 , Fig. 6b ). However, the tumor exposure of the PAMAM-OH dendrimers was greater than that of HPMA copolymers of comparable molecular weights. In spite of a smaller hydrodynamic radius, faster elimination and lesser blood exposure, G7.0-OH (R h 0 4.0 nm) accumulated in the tumor twice as much as HPMA copolymer (131 kDa; R h 08.2 nm) of comparable MW. The tumor to blood exposure ratios indicate that the polymers in circulation passively accumulated in the tumor and this accumulation was greater for the PAMAM dendrimers than the HPMA copolymers under study. The tumor to blood exposure ratios suggest that when in circulation, PAMAM-OH dendrimers have a higher affinity to accumulate in the tumor than the HPMA copolymers (Fig. 7 ).
Blood and tumor extravasation and elimination rate constants
In accordance with the trend in elimination clearance, discussed in detail in the "Elimination clearance-correlation with hydrodynamic size" section, blood elimination rate constant (K 1 ) generally decreased with increase in molecular weight/hydrodynamic size of polymers within a given series ( Table 3) . As a consequence of increased blood circulation, tumor extravasation rate constant (K 2 ) increased with increase in molecular weight/hydrodynamic size within a polymer series (Table 3) . Among the lower molecular weight polymers, G5.0-OH and G6.0-OH extravasated into the tumor faster than their equivalent molecular weight counterparts in the HPMA copolymer series. For the higher molecular weight pomyers-G7.0-OH and HPMA copolymer (131 kDa), tumor extravasation rates were comparable. In agreement with the EPR effect, rate constant K 6 which facilitated prolonged tumor retention of the polymers over the time period of study increased with increase in molecular weight of polymers within a given series (Table 3) . Across polymers of different architecture, the PAMAM dendrimers had K 6 values an order of magnitude higher than the HPMA copolymers of comparable molecular weight. This suggests that PAMAM dendrimers had higher tumor retention than HPMA copolymers in the orthotopic xenograft ovarian tumors under study. This propensity of the Elimination clearance and blood exposure were computed by two-compartmental analysis with bolus input. Renal clearances were computed from urine data. Tumor AUCs were computed from area under the tumor concentration profile curve. Data are presented as mean±standard error Fig. 4 Correlation of elimination clearance of PAMAM-OH dendrimers and HPMA copolymers to hydrodynamic size. Data are represented as mean estimate± standard error of fit PAMAM dendrimers to passively target the tumor was also reflected in tumor to blood exposure ratios of the polymer discussed in the "Tumor exposure" section.
Discussion
Polymeric carriers used in drug delivery have a favorable pharmacokinetic profile over small molecular weight drugs owing to their reduced renal clearance and resulting long circulation half-life in the blood [24] . Unlike small molecular weight drugs which are known to have instantaneous distribution into blood-perfused organs, macromolecular distribution to both target organs such as tumor, and clearance organs such as kidney and liver are limited by their size [24] . Target organs like the tumor are known to have increased uptake and retention of macromolecules due to the enhanced permeability and retention effect [25] . The extent of accumulation of macromolecules in these organs and their blood pharmacokinetics depend on their physicochemical attributes such as chemical composition, molecular weight, hydrodynamic size, charge, extent of plasma protein binding and molecular architecture [26] . Architecture of a polymeric carrier is determined by its molecular conformation, chain flexibility, deforming capability and extent of branching [15] . The polymeric carriers that were evaluated had distinct architectures: PAMAM-OH dendrimers which are hyperbranched polymers with a globular shape while the HPMA copolymers which are linear polymers with side chains known to assume a random coil conformation in solution [20, 21] . PAMAM dendrimers become more rigid at higher generations [5, 20] . With every increase in generation, extent of branching increases and so does surface congestion. This affects the molecular conformation and deforming capability of the dendrimer. The smaller generation PAMAMs (G0.0-3.0) are flexible, floppy, and disc-like. Generations 4.0 through 6.0 have a hollow core and permeable outer shells that render them as nanocontainers. Generations 7.0 onwards, the dendrimers start to possess a very rigid surface scaffolding with a globular shape [5] . The PAMAM-OH dendrimers under study, i.e., G5.0 through G7.0 lie in a range where they transition from a more flexible conformation for G5.0-OH to a more rigid, globular shape for G7.0-OH. The HPMA copolymers on the other hand are not known to undergo a significant conformational change for the range of molecular weights that were studied (26-131 kDa). This trend in molecular conformational change of polymers of different architecture affected their pharmacokinetics. The polymers under study interacted minimally with plasma proteins due to their neutral charge (Section V, online resource). Hence, we do not expect plasma protein binding to influence observed trends in biodistribution and pharmacokinetics. Elimination clearance decreased more rapidly for PAMAM dendrimers with increase in molecular weight or hydrodynamic size than for HPMA copolymers for the same increase in molecular weight (Fig. 3) . These results are in agreement with other studies which show that the shape and ability of the polymer to deform play important roles in the glomerular filtration rate and hence elimination clearance [15, 16, 27, 28] . Previous reports suggest that increased hydrodynamic size, decreased flexibility and increased extent of branching of polymer chains limits passage of a polymer through a pore of comparable size and reduces elimination through the kidneys [15] . In vitro diffusion studies of polymers through porous structures have shown that transport of linear polymers in tissue containing complex extracellular matrix is different from that of branched polymers [23, [29] [30] [31] [32] . The exponent for power law stating the molecular weight dependence on diffusion coefficient through a membrane with defined pore sizes is different for a linear (exponent0−1 to −2.5) versus branched (exponent0 −0.33) polymer. These observations are explained by de Gennes's polymer reptation theory where a linear polymer can move through a network of fibrous obstacles presented by the extracellular matrix while the branched polymer cannot [33] . The branched polymer has to deform in order to diffuse through. In vivo, the glomerular basement membrane, which is a complex fibrous network, is known to be the primary barrier to filtration of neutral macromolecules [34] . Hence, it has been considered fairly realistic to apply the theory of molecular sieving in polymeric gels to the glomerular filtration of macromolecules [34] . For the lower molecular weight polymers, in spite of a higher hydrodynamic radius, G5.0-OH (R h 02.3 nm) eliminated faster than HPMA copolymer (26 kDa; R h 01.4 nm), possibly due to a compact and flexible structure that allowed faster extravasation. The conformational change of PAMAM dendrimers with increase in hydrodynamic size can affect their deforming capability and drastically reduce transport through the capillary endothelium of clearance organs thereby reducing their clearance. G6.0-OH (R h 03.0 nm) eliminated slower than HPMA copolymer (52 kDa; R h 03.3 nm) of comparable MW, possibly due to increased rigidity and consequently slower extravasation. HPMA copolymers, owing to a linear architecture can potentially reptate through pores of capillary endothelium, even if their effective hydrodynamic radii are greater than pore size of fenestration. Hence, even though the elimination clearance for G7.0-OH (R h 0 4.0 nm) was greater than HPMA copolymer (131 kDa; R h 08.2 nm) of comparable MW, the rate at which the elimination clearance changed over a fixed MW range was different for the two polymers of varying architecture. The elimination clearance changed less rapidly with increase in were determined from two-compartmental modeling of blood concentration data using Winnonlin®. K 4 , K 5 , and K 6 were determined from blood-tumor link model fitted to experimental blood and tumor data using a multivariable constrained optimization solver in Matlab® molecular weight and hydrodynamic size of HPMA copolymers as compared to PAMAM dendrimers. In addition to differences in interstitial transport rates of PAMAM-OH dendrimers and HPMA copolymers, their intrinsic differences in physicochemical properties could potentially alter their rate and extent of endocytosis and transcytosis through cells, directly affecting their blood clearances. Extensive kidney accumulation of G5.0-OH and liver accumulation of G6.0-OH also suggests differences in cellular uptake of these polymers based on size and architecture [17] . Renal clearance showed a trend similar to the elimination clearance where along with hydrodynamic size, the polymer architecture affected this parameter (Fig. 5) . The effective pore size for glomerular filtration through the kidney is 3.7-6.0 nm in hydrodynamic diameter [19] . PAMAM G5.0-OH and HPMA copolymer (26 kDa) fall below the size cutoff of glomerular filtration and should readily eliminate through the kidneys. However, renal clearance of G5.0-OH was less than HPMA copolymers of comparable molecular weight since G5.0-OH showed persistent accumulation in the kidney (upto 80 % injected dose) [17] . Limited mechanistic studies for renal retention of PAMAM dendrimers report the localization of these polymers in the lysosomes of proximal tubule cells upon glomerular filtration of the dendrimers [35] . G6.0-OH (R h 03.0 nm) and HPMA copolymer (52 kDa; R h 03.3 nm) are comparable in hydrodynamic size and fall on the threshold of the size cutoff range for kidney filtration. HPMA copolymer (52 kDa) was renally cleared to a higher extent than G6.0-OH. HPMA copolymer (131 kDa; R h 08.2 nm) is twice the hydrodynamic size of G7.0-OH (R h 04.0 nm), and yet was renally cleared to a greater extent than its PAMAM counterpart of comparable MW. This can be explained by the architectural difference in the two constructs. The primary impediment to renal clearance of these polymers is likely to be the tortuous path though the fibrous mesh of the glomerular basement membrane [34] . While the linear HPMA copolymers can potentially reptate through a pore smaller in size than their hydrodynamic radii in a random coil conformation, PAMAM dendrimers have to deform in order to permeate across the pores (Fig. 8) . With increase in molecular weight or generation, the deforming capacity of PAMAM-OH dendrimers is known to decrease, making it harder for higher generation PAMAM-OH dendrimers to sieve through the glomerulus as compared to HPMA copolymers of comparable molecular weights.
Renal clearance was however significantly less than the total elimination clearance suggesting clearance through the liver and spleen. It could also suggest distribution of the polymers into other compartments outside the central compartment (blood). Specifically renal clearance was significantly less for PAMAM dendrimers than HPMA polymers. PAMAM-OH dendrimers showed high liver accumulation (15-50 % injected dose/g of liver tissue), which could potentially facilitate biliary clearance [17] .
Polymer concentration in a given tumor type is a function of plasma clearance rate and vascular exposure along with kinetics of transendothelial transport within the tumor or effective interstitial diffusion coefficient [26, 36] . These factors are governed by a number of physicochemical characteristics of the polymer including size, surface characteristics, shape, and rigidity [26] . Of these properties affecting interstitial tumor transport, the molecular conformation or polymer architecture has been the least studied. In general, polymers with a flexible conformation have demonstrated more ideal tumor transport properties leading to higher tumor accumulation [37] [38] [39] . Findings reported in this paper Fig. 8 Proposed explanation for the difference in elimination clearance of PAMAM-OH dendrimers and HPMA copolymers; adapted from Ref [15] however are contradicting this trend with the globular, rigid PAMAM dendrimers showing higher tumor to blood exposure ratio and extravsation rate constants (K 2 , K 6 ) than the random coil, flexible HPMA copolymers of comparable MW (Fig. 7) . This could be indicative of a phenomenon in the complex fibrous extracellular matrix of angiogenic neovasculature where rigid nanoscale constructs may show higher permeability than coiled polymers that can entangle in the matrix. Besides the conformation, the difference in hydrodynamic size of polymers of varying architecture and comparable molecular weights could also contribute to differences in tumor extravasation rate constant (K 6 ) and total exposure (AUC tumor /dose). For instance, HPMA copolymer (131 kDa; R h 08.2 nm) is twice the hydrodynamic size of G7.0-OH (R h 04.0 nm) of comparable molecular weight. It is known that the primary impediment for the transvascular extravasation of particles across the blood-tumor barrier is at the level of the glycocalyx that coats the surface of pores formed in the trans-endothelial cell fenestrations and interendothelial cell gaps [26, 29] . The luminal glycocalyx layer acts as a nanofilter for transvascular flow creating an effective physiological upper limit of pore size for the bloodtumor barrier [26, 29] . This pore size cutoff can vary for different tumor types and is not precisely known for the orthotopic xenograft A2780 ovarian carcinoma tumors under study. However, based on the pore size range for other tumor types, it could range between the hydrodynamic sizes of HPMA copolymer (131 kDa) and G7.0-OH [40] . This could potentially explain the difference in tumor accumulation of these higher molecular weight polymers. These findings suggest that further investigation and optimization of polymer size and conformation are necessary for optimal tumor transport/accumulation.
Conclusion
Along with molecular weight and hydrodynamic size, polymer architecture was critical in affecting the blood pharmacokinetics of the PAMAM-OH dendrimers and HPMA copolymers. Over the molecular weight range studied, elimination clearance decreased more rapidly with increase in R h for PAMAM-OH dendrimers as compared to HPMA copolymers. Linear HPMA copolymers were eliminated renally to a higher extent than hyperbranched PAMAM-OH dendrimers. These results were indicative of a difference in extravasation of polymers of varying architecture through fenestrations of the kidney tissue. In addition, PAMAM-OH dendrimers had a higher tumor to blood exposure ratio than HPMA copolymers indicating that when in circulation, PAMAM-OH were taken up in the tumor to a greater extent than HPMA copolymers suggesting that polymer architecture influenced tumor extravasation and retention.
